Departments of Surgical Oncology and Pathology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Cancer Biomark. 2010;9(1-6):461-73. doi: 10.3233/CBM-2011-0176.
Renal Cell Carcinoma (RCC) has the highest mortality rate of the genitourinary cancers and the incidence of RCC has risen steadily. If detected early, RCC is curable by surgery although a minority are at risk of recurrence. Increasing incidental detection and an ageing population has led to active surveillance as an option for patients with small renal masses. RCC is heterogeneous and comprises several histological cell types with different genetics, biology and behavior. The identification of the genes predisposing to inherited syndromes with RCC has provided much of our knowledge of the molecular basis of early sporadic RCC. Many of the oncogenes and tumor suppressor genes that are mutated leading to pathway dysregulation in RCC remain to be elucidated. Global studies of copy number, gene sequencing, gene expression, miRNA expression and gene methylation in primary RCC will lead towards this goal. The natural history of RCC indicated by candidate precursor lesions, multifocal or bilateral disease, growth rate of small renal masses under surveillance, and high risk populations provide insight into the behavior of this disease. The use of molecular markers for early detection and prognosis merits more attention with ongoing advances in omics technologies. This review focuses on early RCC, that is disease confined within the renal capsule.
肾细胞癌(RCC)是泌尿生殖系统癌症中死亡率最高的癌症,其发病率一直在稳步上升。如果早期发现,RCC 可以通过手术治愈,尽管少数患者有复发的风险。偶然检测的增加和人口老龄化导致了对小肾癌患者的主动监测作为一种选择。RCC 是异质性的,包括几种具有不同遗传学、生物学和行为的组织学细胞类型。导致 RCC 通路失调的遗传综合征易感基因的鉴定为我们提供了许多关于早期散发性 RCC 分子基础的知识。导致 RCC 中通路失调的许多癌基因和肿瘤抑制基因仍有待阐明。对原发性 RCC 的拷贝数、基因测序、基因表达、miRNA 表达和基因甲基化的全球研究将朝着这一目标前进。候选前体病变、多灶性或双侧疾病、监测中小肾癌的生长速度以及高危人群所提示的 RCC 自然史,使我们能够深入了解这种疾病的行为。随着组学技术的不断进步,分子标志物在早期检测和预后中的应用值得更多关注。本文重点介绍局限于肾包膜内的早期 RCC。